{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:58:15Z","timestamp":1792033095422,"version":"4.4.0"},"reference-count":77,"publisher":"Harborside Press, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>Immunoglobulin light chain (AL) amyloidosis is a clonal plasma cell disorder with multiple clinical presentations. The diagnosis of AL amyloidosis requires a high index of suspicion, making a delay in diagnosis common, which contributes to the high early mortality seen in this disease. Establishing the diagnosis of AL amyloidosis requires the demonstration of tissue deposition of amyloid fibrils. A bone marrow biopsy and fat pad aspirate performed concurrently have a high sensitivity for the diagnosis of AL amyloidosis and negate the need for organ biopsies in most patients. An accurate diagnosis requires amyloid typing via additional testing, including tissue mass spectrometry. Prognostication for AL amyloidosis is largely driven by the organs impacted. Cardiac involvement represents the single most important prognostic marker, and the existing staging systems are driven by cardiac biomarkers. Apart from organ involvement, plasma cell percentage on the bone marrow biopsy, specific fluorescence in situ hybridization findings, age at diagnosis, and performance status are important prognostic markers. This review elaborates on the diagnostic testing and prognostication for patients with newly diagnosed AL amyloidosis.<\/jats:p>","DOI":"10.6004\/jnccn.2022.7077","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T16:33:38Z","timestamp":1673454818000},"page":"83-90","source":"Crossref","is-referenced-by-count":38,"title":["Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment"],"prefix":"10.6004","volume":"21","author":[{"given":"Saurabh","family":"Zanwar","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"J Am Coll Cardiol","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz MA","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ,  Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015;66:2451\u20132466.10.1016\/j.jacc.2015.09.075"},{"key":"B2","series-title":"Amyloid","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson MD","year":"2018","unstructured":"Benson MD, Buxbaum JN, Eisenberg DS,  Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018;25:215\u2013219.10.1080\/13506129.2018.1549825"},{"key":"B3","series-title":"J Intern Med","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar E","year":"2021","unstructured":"Muchtar E, Dispenzieri A, Magen H,  Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med 2021;289:268\u2013292.10.1111\/joim.13169"},{"key":"B4","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar AD","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016;387:2641\u20132654.10.1016\/S0140-6736(15)01274-X"},{"key":"B5","series-title":"Mayo Clin Proc","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015","volume":"94","author":"Kyle RA","year":"2019","unstructured":"Kyle RA, Larson DR, Kurtin PJ,  Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc 2019;94:465\u2013471.10.1016\/j.mayocp.2018.08.041"},{"key":"B6","series-title":"Blood Adv","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock TP","year":"2018","unstructured":"Quock TP, Yan T, Chang E,  Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv 2018;2:1046\u20131053.10.1182\/bloodadvances.2018016402"},{"key":"B7","series-title":"Kidney Int","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/ki.2012.414","article-title":"The diagnosis and characteristics of renal heavy-chain and heavy\/light-chain amyloidosis and their comparison with renal light-chain amyloidosis","volume":"83","author":"Nasr SH","year":"2013","unstructured":"Nasr SH, Said SM, Valeri AM,  The diagnosis and characteristics of renal heavy-chain and heavy\/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int 2013;83:463\u2013470.10.1038\/ki.2012.414"},{"key":"B8","series-title":"Clin Lymphoma Myeloma Leuk","doi-asserted-by":"publisher","first-page":"e826","DOI":"10.1016\/j.clml.2020.06.017","article-title":"How we manage systemic immunoglobulin heavy chain amyloidosis (AH amyloidosis) and immunoglobulin heavy-and-light-chain amyloidosis (AH\/AL amyloidosis)","volume":"20","author":"Chaulagain CP","year":"2020","unstructured":"Chaulagain CP, Herlitz LC, Fu J,  How we manage systemic immunoglobulin heavy chain amyloidosis (AH amyloidosis) and immunoglobulin heavy-and-light-chain amyloidosis (AH\/AL amyloidosis). Clin Lymphoma Myeloma Leuk 2020;20:e826\u2013831.10.1016\/j.clml.2020.06.017"},{"key":"B9","series-title":"Eur J Haematol","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/ejh.13679","article-title":"Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019","volume":"107","author":"Hester LL","year":"2021","unstructured":"Hester LL, Gifkins DM, Bellew K,  Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. Eur J Haematol 2021;107:428\u2013435.10.1111\/ejh.13679"},{"key":"B10","series-title":"Patient","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light chain (AL) amyloidosis: the journey to diagnosis","volume":"11","author":"McCausland KL","year":"2018","unstructured":"McCausland KL, White MK, Guthrie SD,  Light chain (AL) amyloidosis: the journey to diagnosis. Patient 2018;11:207\u2013216.10.1007\/s40271-017-0273-5"},{"key":"B11","series-title":"Am J Hematol","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/ajh.23827","article-title":"Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias","volume":"89","author":"Kourelis TV","year":"2014","unstructured":"Kourelis TV, Kumar SK, Go RS,  Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Am J Hematol 2014;89:1051\u20131054.10.1002\/ajh.23827"},{"key":"B12","series-title":"Leukemia","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41375-018-0286-7","article-title":"Primary systemic amyloidosis in patients with Waldenstr\u00f6m macroglobulinemia","volume":"33","author":"Zanwar S","year":"2019","unstructured":"Zanwar S, Abeykoon JP, Ansell SM,  Primary systemic amyloidosis in patients with Waldenstr\u00f6m macroglobulinemia. Leukemia 2019;33:790\u2013794.10.1038\/s41375-018-0286-7"},{"key":"B13","series-title":"Circ Cardiovasc Imaging","doi-asserted-by":"publisher","first-page":"e005588","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias ED","year":"2017","unstructured":"Pagourelias ED, Mirea O, Duchenne J,  Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging 2017;10:e005588.10.1161\/CIRCIMAGING.116.005588"},{"key":"B14","series-title":"J Am Coll Cardiol","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.jacc.2007.08.028","article-title":"Evaluation and management of the cardiac amyloidosis","volume":"50","author":"Selvanayagam JB","year":"2007","unstructured":"Selvanayagam JB, Hawkins PN, Paul B,  Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101\u20132110.10.1016\/j.jacc.2007.08.028"},{"key":"B15","series-title":"Circulation","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana M","year":"2015","unstructured":"Fontana M, Pica S, Reant P,  Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015;132:1570\u20131579.10.1161\/CIRCULATIONAHA.115.016567"},{"key":"B16","series-title":"Heart Rhythm","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen AV","year":"2008","unstructured":"Kristen AV, Dengler TJ, Hegenbart U,  Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008;5:235\u2013240.10.1016\/j.hrthm.2007.10.016"},{"key":"B17","series-title":"Amyloid","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/13506129.2011.574354036","article-title":"Varied patterns of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients","volume":"18","author":"Adams D","year":"2011","unstructured":"Adams D, Lozeron P, Theaudin M,  Varied patterns of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients. Amyloid 2011;18(Suppl 1):98\u2013100.10.3109\/13506129.2011.574354036"},{"key":"B18","series-title":"Front Neurol","doi-asserted-by":"publisher","first-page":"707134","DOI":"10.3389\/fneur.2021.707134","article-title":"Light-chain amyloidosis with peripheral neuropathy as an initial presentation","volume":"12","author":"Qian M","year":"2021","unstructured":"Qian M, Qin L, Shen K,  Light-chain amyloidosis with peripheral neuropathy as an initial presentation. Front Neurol 2021;12:707134.10.3389\/fneur.2021.707134"},{"key":"B19","series-title":"Am J Hematol","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/ajh.26569","article-title":"Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment","volume":"97","author":"Gertz MA","year":"2022","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol 2022;97:818\u2013829.10.1002\/ajh.26569"},{"key":"B20","series-title":"Br J Haematol","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bjh.14205","article-title":"Natural history of amyloidosis isolated to fat and bone marrow aspirate","volume":"179","author":"Chakraborty R","year":"2017","unstructured":"Chakraborty R, Gertz MA, Dispenzieri A,  Natural history of amyloidosis isolated to fat and bone marrow aspirate. Br J Haematol 2017;179:170\u2013172.10.1111\/bjh.14205"},{"key":"B21","series-title":"Mayo Clin Proc","first-page":"472","article-title":"A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar E","year":"2019","unstructured":"Muchtar E, Gertz MA, Kyle RA,  A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing. Mayo Clin Proc 2019;94:472\u2013483."},{"key":"B22","series-title":"Mayo Clin Proc","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement 2020 update","volume":"96","author":"Muchtar E","year":"2021","unstructured":"Muchtar E, Dispenzieri A, Gertz MA,  Treatment of AL amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement 2020 update. Mayo Clin Proc 2021;96:1546\u20131577.10.1016\/j.mayocp.2021.03.012"},{"key":"B23","series-title":"Semin Hematol","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle RA","year":"1995","unstructured":"Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45\u201359."},{"key":"B24","series-title":"JAMA","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz MA","year":"2020","unstructured":"Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA 2020;324:79\u201389.10.1001\/jama.2020.5493"},{"key":"B25","series-title":"Arthritis Rheum","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/art.21902","article-title":"Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice","volume":"54","author":"van Gameren II","year":"2006","unstructured":"van Gameren II, Hazenberg BP, Bijzet J,  Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 2006;54:2015\u20132021.10.1002\/art.21902"},{"key":"B26","series-title":"Molecules","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.3390\/molecules26123649","article-title":"Combined subcutaneous fat aspirate and skin tru-cut biopsy for amyloid screening in patients with suspected systemic amyloidosis","volume":"26","author":"Hansen CT","year":"2021","unstructured":"Hansen CT, M\u00f8ller HEH, Rojek AM,  Combined subcutaneous fat aspirate and skin tru-cut biopsy for amyloid screening in patients with suspected systemic amyloidosis. Molecules 2021;26:3649.10.3390\/molecules26123649"},{"key":"B27","series-title":"Ann Med","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/07853890.2017.1304649","article-title":"Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition","volume":"49","author":"Muchtar E","year":"2017","unstructured":"Muchtar E, Dispenzieri A, Lacy MQ,  Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Ann Med 2017;49:545\u2013551.10.1080\/07853890.2017.1304649"},{"key":"B28","series-title":"Blood","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini G","year":"2020","unstructured":"Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood 2020;136:2620\u20132627.10.1182\/blood.2020006913"},{"key":"B29","series-title":"Leukemia","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo RL","year":"2012","unstructured":"Comenzo RL, Reece D, Palladini G,  Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012;26:2317\u20132325.10.1038\/leu.2012.100"},{"key":"B30","series-title":"Ther Adv Hematol","doi-asserted-by":"publisher","first-page":"20406207221093962","DOI":"10.1177\/20406207221093962","article-title":"Treatment paradigm in Waldenstr\u00f6m macroglobulinemia: frontline therapy and beyond","volume":"13","author":"Zanwar S","year":"2022","unstructured":"Zanwar S, Abeykoon JP. Treatment paradigm in Waldenstr\u00f6m macroglobulinemia: frontline therapy and beyond. Ther Adv Hematol 2022;13:20406207221093962.10.1177\/20406207221093962"},{"key":"B31","series-title":"Mayo Clin Proc","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples","volume":"95","author":"Dasari S","year":"2020","unstructured":"Dasari S, Theis JD, Vrana JA,  Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples. Mayo Clin Proc 2020;95:1852\u20131864.10.1016\/j.mayocp.2020.06.029"},{"key":"B32","series-title":"J Pathol Clin Res","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/cjp2.126","article-title":"The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis","volume":"5","author":"Rezk T","year":"2019","unstructured":"Rezk T, Gilbertson JA, Mangione PP,  The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. J Pathol Clin Res 2019;5:145\u2013153.10.1002\/cjp2.126"},{"key":"B33","series-title":"Mayo Clin Proc","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.mayocp.2021.04.023","article-title":"Artificial intelligence-enhanced electrocardiogram for the early detection of cardiac amyloidosis","volume":"96","author":"Grogan M","year":"2021","unstructured":"Grogan M, Lopez-Jimenez F, Cohen-Shelly M,  Artificial intelligence-enhanced electrocardiogram for the early detection of cardiac amyloidosis. Mayo Clin Proc 2021;96:2768\u20132778.10.1016\/j.mayocp.2021.04.023"},{"key":"B34","series-title":"Circulation","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore JD","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH,  Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404\u20132412.10.1161\/CIRCULATIONAHA.116.021612"},{"key":"B35","series-title":"EJNMMI Phys","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40658-020-00342-7","article-title":"Assessment of cardiac amyloidosis with 99mTc-pyrophosphate (PYP) quantitative SPECT","volume":"8","author":"Ren C","year":"2021","unstructured":"Ren C, Ren J, Tian Z,  Assessment of cardiac amyloidosis with 99mTc-pyrophosphate (PYP) quantitative SPECT. EJNMMI Phys 2021;8:3.10.1186\/s40658-020-00342-7"},{"key":"B36","series-title":"Medicine (Baltimore)","doi-asserted-by":"publisher","first-page":"e25582","DOI":"10.1097\/MD.0000000000025582","article-title":"False positive technetium-99m pyrophosphate scintigraphy in a patient with cardiac amyloidosis light chain: case report","volume":"100","author":"Zeng Y","year":"2021","unstructured":"Zeng Y, Poterucha TJ, Einstein AJ,  False positive technetium-99m pyrophosphate scintigraphy in a patient with cardiac amyloidosis light chain: case report. Medicine (Baltimore) 2021;100:e25582.10.1097\/MD.0000000000025582"},{"key":"B37","series-title":"Am J Hematol","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/ajh.20829","article-title":"Association of acquired von Willebrand syndrome with AL amyloidosis","volume":"82","author":"Kos CA","year":"2007","unstructured":"Kos CA, Ward JE, Malek K,  Association of acquired von Willebrand syndrome with AL amyloidosis. Am J Hematol 2007;82:363\u2013367.10.1002\/ajh.20829"},{"key":"B38","series-title":"Blood","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar E","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK,  Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood 2017;129:2111\u20132119.10.1182\/blood-2016-11-751628"},{"key":"B39","series-title":"Blood Cancer J","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron A","year":"2021","unstructured":"Staron A, Zheng L, Doros G,  Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J 2021;11:139.10.1038\/s41408-021-00529-w"},{"key":"B40","series-title":"JACC Heart Fail","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jchf.2019.07.007","article-title":"A changing landscape of mortality for systemic light chain amyloidosis","volume":"7","author":"Barrett CD","year":"2019","unstructured":"Barrett CD, Dobos K, Liedtke M,  A changing landscape of mortality for systemic light chain amyloidosis. JACC Heart Fail 2019;7:958\u2013966.10.1016\/j.jchf.2019.07.007"},{"key":"B41","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMc1917321","article-title":"Epidemiologic and survival trends in amyloidosis, 1987-2019","volume":"382","author":"Ravichandran S","year":"2020","unstructured":"Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis, 1987-2019. N Engl J Med 2020;382:1567\u20131568.10.1056\/NEJMc1917321"},{"key":"B42","series-title":"Br J Haematol","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/bjh.16096","article-title":"Ten-year survivors in AL amyloidosis: characteristics and treatment pattern","volume":"187","author":"Muchtar E","year":"2019","unstructured":"Muchtar E, Gertz MA, Lacy MQ,  Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. Br J Haematol 2019;187:588\u2013594.10.1111\/bjh.16096"},{"key":"B43","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri A","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA,  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751\u20133757.10.1200\/JCO.2004.03.029"},{"key":"B44","series-title":"Blood","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar AD","year":"2013","unstructured":"Wechalekar AD, Schonland SO, Kastritis E,  A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121:3420\u20133427.10.1182\/blood-2012-12-473066"},{"key":"B45","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar S","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ,  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989\u2013995.10.1200\/JCO.2011.38.5724"},{"key":"B46","series-title":"Blood","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness B","year":"2019","unstructured":"Lilleness B, Ruberg FL, Mussinelli R,  Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood 2019;133:215\u2013223.10.1182\/blood-2018-06-858951"},{"key":"B47","series-title":"Leukemia","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/leu.2016.191","article-title":"Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis","volume":"30","author":"Merlini G","year":"2016","unstructured":"Merlini G, Lousada I, Ando Y,  Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia 2016;30:1979\u20131986.10.1038\/leu.2016.191"},{"key":"B48","series-title":"Blood","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2018-10-875252","article-title":"Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay","volume":"133","author":"Muchtar E","year":"2019","unstructured":"Muchtar E, Kumar SK, Gertz MA,  Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. Blood 2019;133:763\u2013766.10.1182\/blood-2018-10-875252"},{"key":"B49","series-title":"Subcell Biochem","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/978-94-007-5416-4_22","article-title":"The challenge of systemic immunoglobulin light-chain amyloidosis (AL)","volume":"65","author":"Palladini G","year":"2012","unstructured":"Palladini G, Comenzo RL. The challenge of systemic immunoglobulin light-chain amyloidosis (AL). Subcell Biochem 2012;65:609\u2013642.10.1007\/978-94-007-5416-4_22"},{"key":"B50","series-title":"Blood","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini G","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P,  A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014;124:2325\u20132332.10.1182\/blood-2014-04-570010"},{"key":"B51","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis TV","year":"2013","unstructured":"Kourelis TV, Kumar SK, Gertz MA,  Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013;31:4319\u20134324.10.1200\/JCO.2013.50.8499"},{"key":"B52","series-title":"Amyloid","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/13506129.2018.1443439","article-title":"Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome","volume":"25","author":"Tovar N","year":"2018","unstructured":"Tovar N, Rodr\u00edguez-Lobato LG, Cibeira MT,  Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. Amyloid 2018;25:79\u201385.10.1080\/13506129.2018.1443439"},{"key":"B53","series-title":"Biol Blood Marrow Transplant","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.bbmt.2016.05.027","article-title":"The effect of bone marrow plasma cell burden on survival in patients with light chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation","volume":"22","author":"Dittus C","year":"2016","unstructured":"Dittus C, Uwumugambi N, Sun F,  The effect of bone marrow plasma cell burden on survival in patients with light chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transplant 2016;22:1729\u20131732.10.1016\/j.bbmt.2016.05.027"},{"key":"B54","series-title":"Leukemia","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41375-019-0655-x","article-title":"Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis","volume":"34","author":"Muchtar E","year":"2020","unstructured":"Muchtar E, Gertz MA, Kourelis TV,  Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia 2020;34:1135\u20131143.10.1038\/s41375-019-0655-x"},{"key":"B55","series-title":"Blood Adv","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1182\/bloodadvances.2018023200","article-title":"Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma","volume":"2","author":"Bochtler T","year":"2018","unstructured":"Bochtler T, Merz M, Hielscher T,  Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Adv 2018;2:2607\u20132618.10.1182\/bloodadvances.2018023200"},{"key":"B56","series-title":"Haematologica","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3324\/haematol.13369","article-title":"Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis","volume":"94","author":"Bryce AH","year":"2009","unstructured":"Bryce AH, Ketterling RP, Gertz MA,  Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009;94:380\u2013386.10.3324\/haematol.13369"},{"key":"B57","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler T","year":"2015","unstructured":"Bochtler T, Hegenbart U, Kunz C,  Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol 2015;33:1371\u20131378.10.1200\/JCO.2014.57.4947"},{"key":"B58","series-title":"Cancer Med","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/cam4.3683","article-title":"AL amyloidosis: the effect of fluorescent in situ hybridization abnormalities on organ involvement and survival","volume":"10","author":"Ozga M","year":"2021","unstructured":"Ozga M, Zhao Q, Benson D Jr,  AL amyloidosis: the effect of fluorescent in situ hybridization abnormalities on organ involvement and survival. Cancer Med 2021;10:965\u2013973.10.1002\/cam4.3683"},{"key":"B59","series-title":"Amyloid","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/13506129.2020.1778461","article-title":"Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen","volume":"27","author":"Dumas B","year":"2020","unstructured":"Dumas B, Yameen H, Sarosiek S,  Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. Amyloid 2020;27:244\u2013249.10.1080\/13506129.2020.1778461"},{"key":"B60","series-title":"Blood Cancer J","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41408-020-0321-6","article-title":"Venetoclax for the treatment of translocation (11;14) AL amyloidosis","volume":"10","author":"Sidiqi MH","year":"2020","unstructured":"Sidiqi MH, Al Saleh AS, Leung N,  Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer J 2020;10:55.10.1038\/s41408-020-0321-6"},{"key":"B61","series-title":"Leukemia","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar E","year":"2017","unstructured":"Muchtar E, Dispenzieri A, Kumar SK,  Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia 2017;31:1562\u20131569.10.1038\/leu.2016.369"},{"key":"B62","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini G","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA,  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541\u20134549.10.1200\/JCO.2011.37.7614"},{"key":"B63","series-title":"Blood Cancer J","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41408-020-00355-6","article-title":"Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy","volume":"10","author":"Milani P","year":"2020","unstructured":"Milani P, Basset M, Nuvolone M,  Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy. Blood Cancer J 2020;10:90.10.1038\/s41408-020-00355-6"},{"key":"B64","series-title":"Leukemia","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41375-018-0258-y","article-title":"Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio","volume":"33","author":"Muchtar E","year":"2019","unstructured":"Muchtar E, Dispenzieri A, Leung N,  Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia 2019;33:527\u2013531.10.1038\/s41375-018-0258-y"},{"key":"B65","series-title":"Blood Cancer J","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41408-020-0325-2","article-title":"The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis","volume":"10","author":"Cohen OC","year":"2020","unstructured":"Cohen OC, Law S, Lachmann HJ,  The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis. Blood Cancer J 2020; 10:60.10.1038\/s41408-020-0325-2"},{"key":"B66","series-title":"Blood Cancer J","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-020-00354-7","article-title":"Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis","volume":"10","author":"Sarosiek S","year":"2020","unstructured":"Sarosiek S, Zheng L, Sloan JM,  Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. Blood Cancer J 2020;10:88.10.1038\/s41408-020-00354-7"},{"key":"B67","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis E","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC,  Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 2021;385:46\u201358.10.1056\/NEJMoa2028631"},{"key":"B68","series-title":"Blood","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","author":"Milani P","year":"2017","unstructured":"Milani P, Basset M, Russo F,  Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood 2017;130:625\u2013631.10.1182\/blood-2017-02-767467"},{"key":"B69","series-title":"Blood","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich T","year":"2017","unstructured":"Dittrich T, Bochtler T, Kimmich C,  AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood 2017;130:632\u2013642.10.1182\/blood-2017-02-767475"},{"key":"B70","series-title":"Amyloid","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/13506129.2019.1666709","article-title":"Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis","volume":"27","author":"Muchtar E","year":"2020","unstructured":"Muchtar E, Dispenzieri A, Jevremovic D,  Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid 2020;27:13\u201316.10.1080\/13506129.2019.1666709"},{"key":"B71","series-title":"Blood Cancer J","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-021-00428-0","article-title":"Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis","volume":"11","author":"Palladini G","year":"2021","unstructured":"Palladini G, Paiva B, Wechalekar A,  Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer J 2021; 11:34.10.1038\/s41408-021-00428-0"},{"key":"B72","series-title":"Leukemia","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar E","year":"2018","unstructured":"Muchtar E, Dispenzieri A, Leung N,  Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia 2018;32:2240\u20132249.10.1038\/s41375-018-0060-x"},{"key":"B73","series-title":"Blood","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1182\/blood-2021-149594","article-title":"Graded renal response criteria for light chain (AL) amyloidosis","volume":"138","author":"Muchtar E","year":"2021","unstructured":"Muchtar E, Wisniowski B, Palladini G,  Graded renal response criteria for light chain (AL) amyloidosis. Blood 2021;138(Suppl 1):2724.10.1182\/blood-2021-149594"},{"key":"B74","series-title":"Blood","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1182\/blood-2021-149222","article-title":"Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival","volume":"138","author":"Muchtar E","year":"2021","unstructured":"Muchtar E, Dispenzieri A, Wisniowski B,  Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival. Blood 2021;138(Suppl 1):2720.10.1182\/blood-2021-149222"},{"key":"B75","series-title":"Leukemia","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41375-018-0370-z","article-title":"Comparative analysis of staging systems in AL amyloidosis","volume":"33","author":"Muchtar E","year":"2019","unstructured":"Muchtar E, Therneau TM, Larson DR,  Comparative analysis of staging systems in AL amyloidosis. Leukemia 2019;33:811\u2013814.10.1038\/s41375-018-0370-z"},{"key":"B76","series-title":"Haematologica","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3324\/haematol.2015.128025","article-title":"Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis","volume":"100","author":"Sachchithanantham S","year":"2015","unstructured":"Sachchithanantham S, Offer M, Venner C,  Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis. Haematologica 2015;100:1469\u20131476.10.3324\/haematol.2015.128025"},{"key":"B77","series-title":"Amyloid","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/13506129409148623","article-title":"Autonomic neuropathy in AL (primary) amyloidosis and its effect on survival","volume":"1","author":"Berg AM","year":"1994","unstructured":"Berg AM, Anderson JJ, Chipkin SR,  Autonomic neuropathy in AL (primary) amyloidosis and its effect on survival. Amyloid 1994; 1:39\u201346.10.3109\/13506129409148623"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/1\/article-p83.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/1\/article-p83.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/1\/article-p83.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T16:34:27Z","timestamp":1673454867000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/1\/article-p83.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":77,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2022.7077","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}